Two Sigma Advisers
KYTX icon

Two Sigma Advisers’s Kyverna Therapeutics KYTX Stock Holding History

Two Sigma Advisers’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-49,400
Closed -$464K – 2231
2025
Q4 		$464K Sell
49,400
-31,900
-39% -$237K ﹤0.01% 1819
2025
Q3 		$488K Sell
81,300
-13,000
-14% -$52K ﹤0.01% 1774
2025
Q2 		$290K Buy
94,300
+13,400
+17% +$33.1K ﹤0.01% 1972
2025
Q1 		$156K Buy
80,900
+610
+0.8% +$1.8K ﹤0.01% 2180
2024
Q4 		$300K Buy
80,290
+63,390
+375% +$304K ﹤0.01% 1984
2024
Q3 		$82.6K Buy
+16,900
New +$130K ﹤0.01% 2182

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Two Sigma Advisers's KYTX Position: Q1 2026 in Review

Two Sigma Advisers sold out of Kyverna Therapeutics (KYTX) in Q1 2026, closing a stake of 49,400 shares — an estimated $464K sold.

Two Sigma Advisers first reported a position in KYTX in Q3 2024 and held it in 6 quarters. The position peaked at $488K in Q3 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Two Sigma Advisers reported no remaining Kyverna Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 49,400 Kyverna Therapeutics shares in Q1 2026, an estimated $464K.
  • Two Sigma Advisers first reported a position in Kyverna Therapeutics in Q3 2024 and held it in 6 quarters.
  • Two Sigma Advisers's Kyverna Therapeutics position peaked at $488K in Q3 2025.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.